Phase II study of mitoxantrone in epithelial ovarian cancer.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Cancer treatment reports

• Publication date

  1987-06-01

• Fields of study

  Medicine

• Identifiers
  PMID 3581101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mitoxantrone in epithelial carcinoma of the ovary: A Southwest Oncology Group study

  1984cited by this paper
• Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.

  1984cited by this paper
• Mitoxantrone (NSC‐3O1739) in patients with advanced ovarian carcinoma: A phase II study of the Gynecologic Oncology Group

  1984cited by this paper
• Chemotherapy of ovarian cancer.

  1984cited by this paper
• Mitoxantrone (novantrone): a review of experimental and early clinical studies.

  1983cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• Epithelial carcinoma of the ovary: current strategies.

  1981cited by this paper
• Role of cytoreductive surgical treatment in the management of advanced ovarian cancer.

  1979cited by this paper

• Thermal dewetting tunes surface enhanced resonance Raman scattering (SERRS) performance

  2018cites this paper
• O . Group Study on Second-line Treatment in Advanced Epithelial Ovarian Cancer : an Attempt to Identify Clinical and Biological F actors Determining Prognosis

  2015cites this paper
• Fluorescent DNA-Protected Silver Nanoclusters for Ligand-HIV RNA Interaction Assay.

  2015cites this paper
• Nanodiamond–Mitoxantrone Complexes Enhance Drug Retention in Chemoresistant Breast Cancer Cells

  2014cites this paper
• The Current and Future Place of Vinorelbine in Cancer Therapy

  2012cites this paper
• Cells in the Absence of P-Glycoprotein Overexpression Multidrug Resistance in Mitoxantrone-selected HL-60 Leukemia Updated

  2006cites this paper
• Biological fingerprinting analysis by liquid chromatography/mass spectrometry for evaluation of DNA structural selectivity of multiple compounds in natural products.

  2006cites this paper
• Mitoxantrone-resistant Human MCF-7 Breast Cancer Cells 1 ) Overexpression in mdr P-Glycoprotein ( Reduced Intracellular Drug Accumulation in the Absence of Updated

  2006cites this paper
• Dose Intensity in Advanced Ovarian Cancer : Have We Answered the Question ?

  2005cites this paper
• A phase II study of mitozantrone in advanced carcinoma of the ovary

  2004cites this paper
• Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer

  2004cites this paper
• Chemotherapy for advanced epithelial ovarian carcinoma.

  2002cites this paper
• Anthracyclines in the treatment of gynecologic malignancies.

  2002cites this paper
• Quantitative analysis of mitoxantrone by surface-enhanced resonance Raman scattering.

  2002cites this paper
• Elderly ovarian cancer: treatment with mitoxantrone-carboplatin.

  2001cites this paper
• Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.

  1998cites this paper
• Intraperitoneal cisplatin--mitoxantrone in ovarian cancer patients with minimal residual disease.

  1997cites this paper
• Intraperitoneal Chemotherapy with Mitoxanthrone in Ovarian Cancer

  1997cites this paper
• Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.

  1997cites this paper
• A phase I–II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma

  1997cites this paper
• A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer

  1996cites this paper
• Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer.

  1996cites this paper
• Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.

  1996cites this paper
• Mitoxantrone is effective in treating childhood T‐cell lymphoma/T‐cell acute lymphoblastic leukemia

  1995cites this paper
• An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis.

  1995cites this paper
• Dose intensity in advanced ovarian cancer: have we answered the question?

  1995cites this paper
• Mitoxantrone and ifosfamide as second-line therapy of epithelial ovarian cancer. A pilot study by the I.T.M.O. Group.

  1994cites this paper
• An Intensive Treatment with Mitoxantrone and Ifosfamide in Second-Line Therapy of Epithelial Ovarian Cancer

  1994cites this paper
• Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma.

  1994cites this paper
• The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.

  1994cites this paper
• Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer.

  1993cites this paper
• Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies

  1993cites this paper
• Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.

  1992cites this paper
• Determination of intraperitoneal mitoxantrone in the serum of cancer patients using a high performance liquid chromatograph coupled to an Advanced Automated Sample Processor (AASP).

  1992cites this paper
• Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

  1991cites this paper
• Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.

  1991cites this paper
• Phase II studies: wrong doses, wrong patients?

  1991cites this paper
• Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.

  1991cites this paper
• Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial.

  1991cites this paper
• Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.

  1990cites this paper
• Mitoxantrone: potential for use in intensive therapy.

  1990cites this paper
• Experimental and clinical status of intraperitoneal chemotherapy.

  1990cites this paper
• Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer.

  1990cites this paper
• Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.

  1989cites this paper
• Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

  1989cites this paper
• Intraperitoneal therapy in the management of ovarian carcinoma.

  1989cites this paper
• Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers.

  1989cites this paper
• Mitoxantrone: An Active Agent in Refractory Non‐Hodgkin's Lymphomas

  1988cites this paper
• Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration.

  1988cites this paper
• A Phase II Study of Mitoxantrone

  1988cites this paper
• Mitoxantrone: an active, new antitumor agent with an improved therapeutic index.

  1987cites this paper
• Chemotherapy for advanced or recurrent gynecologic cancer

  1987cites this paper
• Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity.

  1986cites this paper